Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Equity Ratio (2017 - 2025)

Puma Biotechnology's Equity Ratio history spans 9 years, with the latest figure at 0.6 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 39.54% year-over-year to 0.6; the TTM value through Dec 2025 reached 0.6, up 39.54%, while the annual FY2025 figure was 0.6, 39.54% up from the prior year.
  • Equity Ratio reached 0.6 in Q4 2025 per PBYI's latest filing, up from 0.57 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.6 in Q4 2025 to a low of 0.05 in Q3 2021.
  • Average Equity Ratio over 5 years is 0.23, with a median of 0.17 recorded in 2023.
  • Peak YoY movement for Equity Ratio: plummeted 2688.3% in 2021, then skyrocketed 1001.41% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.01 in 2021, then surged by 1001.41% to 0.1 in 2022, then surged by 138.24% to 0.23 in 2023, then soared by 86.28% to 0.43 in 2024, then surged by 39.54% to 0.6 in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Equity Ratio are 0.6 (Q4 2025), 0.57 (Q3 2025), and 0.54 (Q2 2025).